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Abstract 
Background: Heat shock protein 27 (HSP27) is an intracellular molecular chaperone that is 
expressed at high levels following the exposure of cells to environmental stressors such as 
heat, toxins, and free radicals. High levels of HSP antigens and antibody titers have been 
reported in several conditions including cardiovascular disease and cancers. We measured 
serum anti-HSP27 antibody levels in 993 subjects and assessed the associations between 
serum anti-HSP27 antibody levels and demographic characteristics including coronary risk 
factors. 
Methods: A total of 993 subjects were recruited as part of the Mashhad Stroke and Heart 
Atherosclerotic Disorders (MASHAD) cohort study. Demographic, clinical, and biochemical 
parameters and serum anti-HSP27 antibody titers were determined in all the subjects. 
Results: Serum anti-HSP27 antibody levels increased with increasing age in men. No 
significant differences in levels were detected between men and women. Serum anti-HSP27 
antibody levels were significantly higher in obese subjects than in nonobese subjects 
(P=0.046); however, no significant influence of smoking status was observed. Moreover, 
serum anti-HSP27 antibody titers were positively associated with age, body mass index, 
waist/hip ratio, the presence of diabetes mellitus, nonsmoking habit, serum triglycerides, 
cholesterol, and high-sensitivity c-reactive protein. 
Conclusion: We have found that serum anti-HSP27 antibody titers are related to several 
cardiovascular risk factors, necessitating further studies on the value of this emerging marker 
for risk stratification. 
 
Keywords: Anti-heat Shock Protein 27, Cardiovascular Risk Factors, Determinants 
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Introduction: 
Heat shock protein 27 (HSP27) is an intracellular molecular chaperone that is expressed in 
response to the exposure of cells to environmental stressors (1) and increases the ability of 
cells to overcome environmental stress (2). HSPs modify several aspects of cell function, 
including differentiation, apoptosis, and the repair and refolding of denatured proteins (3). 
They are associated with cell exposure to a wide variety of environmental stresses including 
high temperature, viral infection, oxidative stress, ischemia, heavy metals, ultraviolet 
irradiation, and reactive oxygen species (ROS) (4).  
HSPs are highly immunogenic, and it is believed that an autoimmune response to HSPs 
contributes to rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus 
erythematosus (5, 6), and diabetes mellitus (1). There are several HSP families of proteins: 
HSPH (former name HSP110), HSPC (HSP90), HSPA (HSP70), HSPD/E (HSP60/HSP10), 
CCT (TRiC), DNAJ (HSP40), and HSPB (small HSP or sHSP) including HSP27 (7). HSP27 
is a member of the sHSP family of proteins (8), and high serum titers of this protein have 
been reported in individuals with cardiovascular disease (CVD) (9). HSP27 has been 
suggested as a marker of inflammation (10), and immune response to HSPs may contribute to 
the progression of atherosclerosis. Anti-HSP27 antibodies titers were increased during 
atherogenesis (9, 11). Serum anti-HSP27 antibody titers have been suggested to predict 
outcomes in cancer and may help to identify individuals at high risk of CVD (1).  
There is growing evidence of a relationship between HSPs and inflammatory diseases, 
including CVD. Most studies have focused on HSP/anti-HSP60, 65, and 70, although recent 
data support the role of HSP/anti-HSP27 in CVD, which is the leading cause of death 
worldwide (9, 12, 13).  
We have previously demonstrated an association between hypertension and serum anti-
HSP27 antibody levels; however, the association with diabetes mellitus and smoking status 
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was not statistically significant for a sample of 168 patients. Moreover, we previously 
reported a relationship between anti-HSP27 antibody levels and risk of myocardial infarction 
(13). The present study aimed to investigate serum anti-HSP27 antibody levels and determine 
factors affecting it in a large population.  
 
 
Materials and methods: 
Population 
A total of 933 subjects, including 456 men and 477 women, of age 35-64 years, were enrolled 
as part of the Mashhad Stroke and Heart Atherosclerotic Disorders Study, Mashhad 
University of Medical Sciences (14). Exclusion criteria included subjects with severe 
hypertension, CVD or history of CVD, cerebrovascular disease, endocrine abnormalities, 
infectious disease, diabetes mellitus, and pregnant or breastfeeding women (14, 15). The 
protocol was approved by the Ethics Committee of Mashhad University of Medical Sciences, 
and all the subjects provided written informed consent to participate in the study. 
Anthropometric measurements  
Anthropometric parameters including height, body weight, waist circumference, and hip 
circumference were measured for all participants as described previously (15). Body mass 
index (BMI) was calculated as weight (kg) divided by height squared (m
2
). In addition, we 
collected information about the socioeconomic status of our subjects. The subjects were 
divided into three subgroups: obese (BMI≥30 kg/m2), overweight (30>BMI≥25 kg/m2), and 
normal weight (BMI<25 kg/m
2
) (14, 15).  
Biochemical analysis 
Lipid profile, including total cholesterol, triglycerides, high-density lipoprotein cholesterol 
(HDL-C), and low-density lipoprotein cholesterol (LDL-C), was evaluated in all the subjects. 
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Fasting blood glucose (FBG) levels were measured as described before (14-15) using the BT-
3000 auto-analyzer machine (Biotechnica, Rome, Italy). High-sensitivity C-reactive protein 
(hs-CRP) was measured by a PEG-enhanced immunoturbidimetry method using an Alycon 
analyzer (ABBOTT, Chicago, IL, USA).  
Serum anti-HSP27 antibody titer measurements 
Anti-HSP27 antibody titers were determined in serum as previously described (16, 17). 
Briefly, microtiter plates (Nunc Maxisorp, 3Nunc) were coated with 100 ng of recombinant 
human HSP27 dissolved in 50 μL of carbonate buffer followed by incubation for 18 h at 4 
°C. The wells were washed thrice with wash buffer (Phosphate-buffered saline (PBS) 
containing 0.05% Tween-20). Nonspecific binding was reduced by blocking each well with 
2% goat serum in PBS: 250 μL added to each well and incubated for 30 min at 37 °C and 30 
min at room temperature. Serum was diluted to 1:100 with 2% goat serum in PBS. After 
washing, 100 μL of peroxidase-conjugated goat anti-human IgG (Sigma-Aldrich, 4Inc., USA) 
diluted to 1:500 with 2% goat serum in PBS was added to each well and incubated for 30 min 
at room temperature. Subsequently, 100 μL of tetramethylbenzidine (TMB) substrate [200 μL 
of 6 mg⁄mL TMB in Dimethyl Sulfoxide (DMSO) added to 10 mL of 50 mM acetate buffer, 
pH 4.5, containing 6 μL of hydrogen peroxide (H2O2)] was added to each well, and the plate 
was incubated for 15 min in the dark at room temperature. The reaction was terminated by 
adding 50 μL of 2 M HCl to each well. Optical density was measured using a Labsystems 
iEMS Reader Microtiter plate reader. After correction for nonspecific background absorbance 
(subtracting the absorbance of uncoated wells from the antigen-coated wells for each 
sample), the results were expressed in optical density units. 
 
Statistical analysis 
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Data were analyzed using SPSS software (version 11.5). The normality of distribution was 
assessed using the Kolmogorov-Smirnov test. Descriptive statistics (mean±standard deviation 
(SD) or median±interquartile range (IQR) were determined for normally or non-normally 
distributed variables, respectively. For normally and non-normally distributed variables, 
Student’s t-test and Mann-Whitney U test were used, respectively, to compare the clinical 
characteristics and baseline demographics between the groups. Chi-square test and/or Fisher 
exact test were used for comparing categorical variables. Pearson and Spearman correlation 
tests were used to show significant correlation between two normal and two non-normal 
quantitative variables, respectively. Non-normally distributed data were analyzed by 
Kruskal–Wallis test (for more than two groups). Spearman correlation was used to investigate 
the relationship between the anti-HSP antibody titers and atherosclerosis risk factors 
including age, serum total cholesterol, hs-CRP, triglyceride, HDL-C, LDL-C, 
cholesterol/HDL-C ratio, BMI, systolic and diastolic blood pressure, FBG, and waist and hip 
circumferences, height, and waist/hip ratio. We determined the factors that were significantly 
related to serum HSP27 antibody titers using stepwise multiple regression. A two-sided 
P<0.05 was considered significant. 
Results 
Effect of gender, age, and smoking status on serum anti-HSP27 antibody levels 
As shown in Table 1, age, FBG, waist/hip ratio, LDL-C, serum triglycerides, systolic blood 
pressure, and presence of other CVD risk factors including diabetes mellitus and 
hypertension (P>0.05) were not significantly different between the groups. However, women 
had a significantly higher BMI, waist and hip circumferences, HDL-C, and hs-CRP (Table 1). 
Serum anti-HSP27 antibody levels did not differ between men and women. Similar results 
were also observed after dividing the participants in to age cohorts: 35-44, 45-54, and 55-65 
years (Table 2).  
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Effect of BMI on serum anti-HSP27 antibody level 
Obese subjects had significantly higher BMI, waist/hip ratio, FBG, serum triglyceride, hs-
CRP, SBP/DBP, and LDL-C; HDL-C levels were lower in obese than in nonobese subjects 
(P<0.05). Hypertension and dyslipidemia were more common in the obese subjects than in 
the nonobese subjects (Table 3). Serum anti-HSP27 antibody titer was significantly higher in 
the obese subjects than in the nonobese subjects (P=0.046, Table 5). After adjustment, the 
differences between the groups remained significant (BMI: β=0.036, P=0.037).  
Effect of socioeconomic status on serum anti-HSP27 antibody levels 
Subjects were divided into six subgroups of educational attainment: primary school, 
secondary school, high school, diploma, bachelor or postgraduate, and PhD or MD. Serum 
anti-HSP27 antibody titers were not significantly different between the groups. Similar 
results were observed for the effect of employment status on anti-HSP27 antibody levels 
(Table 4-5).  
Effect of atherosclerosis risk factors on anti-HSP27 antibody levels 
Associations between anti-HSP27 antibody levels and atherosclerosis risk factors were 
assessed by general linear model analysis as the dependent variable (anti-HSP27) is 
quantitative and independent variables are both qualitative and quantitative. These results 
showed that age, BMI, waist/hip ratio, triglycerides, cholesterol, hs-CRP, hyperlipidemia, and 
hypertension were positively associated with serum anti-HSP27 antibody titers (Table 6). 
Discussion 
To the best of our knowledge, this is the first study evaluating the effect of demographic 
characteristics and socioeconomic status with respect to serum anti-HSP27 antibody titers. 
We found that obese subjects had significantly higher anti-HSP27 antibody titers than the 
nonobese group, which is in agreement with our previous report (16). Therefore, our recent 
data suggest that this biological marker can be used as a novel risk biomarker for CVDs.  
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There is growing body of data suggesting the important role of this marker in CAD and 
stroke (12-13, 16-18). In the present study, we also investigated its relationship with age. Our 
data showed that serum anti-HSP27 antibody titer did not differ with gender, which is 
consistent with the results of Zilaee et al, who observed no significant relationship between 
gender and antibody titers to HSP27 and 60 (18). Moreover, Rea et al, in a study of 60 
individuals aged between 20 and 96 years, showed that the anti-HSP70 antibody levels 
increased significantly with age (19). Another study also reported that serum anti-HSP27 
antibody levels increased with age, and it was associated with hypertension (20). We found a 
significant increase in anti-HSP27 antibody levels with respect to age in the male subgroup, 
which is in agreement with a previous report (20). Moreover, we explored the effect of 
smoking status on serum anti-HSP27 antibody titers. However, no statistically significant 
differences were observed between groups, which is consistent with our previous data (21).  
There is accumulating evidence showing the association of inflammatory markers such as 
CRP, TNF-α, and IL-6 with obesity (22). Our previous data revealed the association of body 
mass and antibody titers to HSP60, 65, and 70 in 170 healthy Caucasians (23). In the current 
study, we showed for the first time the important role of serum anti-HSP27 antibody titers as 
a biomarker in obese subjects. Previous studies have shown that serum anti-HSP27 antibody 
levels may reflect inflammatory status (10, 23). The role of anti-HSP antibody titers has been 
shown during the process of atherosclerosis (9, 11), and the high levels of anti-HSP27 
antibodies in obese subjects suggest that an immune response to HSPs contributes to the 
progression of atherosclerosis in these subjects. 
The effect of socioeconomic status on serum anti-HSP27 antibody titers was studied in our 
population, although no statistically significant relationship was observed for these 
parameters. Victora et al (2007) showed no association between serum anti-HSP60 antibody 
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titers and maternal schooling, skin color, or any other socioeconomic or environmental status 
(24).  
A major strength of the present study is that it was performed in a large number of subjects, 
and the effect of demographic, biochemical, and socioeconomic status of the population on 
the anti-HSP27 antibody levels was studied. Moreover, this is the first study showing the 
effect of obesity, a risk factor for CVD, on the level of serum anti-HSP27 antibody titers. 
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Table 1: Comparison of clinical and biochemical characteristics between men and women 
 Total men women p-value 
 933 456 477 - 
Age (year) 47.35±7.97 47.37±7.97 47.34±7.98 0.974 
Height (m) 1.62±0.09 1.69±0.07 1.56±0.06 0.001 
Weight (kg) 73.44±13.14 75.75±13.7 71.24±12.2 0.001 
BMI (kg/m
2
) 27.92±4.75 26.39±4.32 29.39±4.69 0.001 
FBG (mg/dL) 90.16±35.32 90.37±30.92 89.96±39.11 0.081 
WC (cm) 95.58±12.25 93.49±11.07 97.56±12.98 0.001 
HC (cm) 103.72±9.34 101.06±8.05 106.27±9.78 0.001 
WHR 0.92±0.09 0.93±0.1 0.92±0.09 0.635 
Serum LDL-C (mg/dL) 116.17±36.7 113.85±36.25 118.39±37.02 0.064 
Serum HDL-C (mg/dL) 42.42±9.91 40.05±9.73 44.71±9.55 0.001 
Serum TG (mg/dL) 116(84-168) 121 (87-172) 113 (81-162) 0.153 
Serum hs-CRP (mg/dL) 1.61(1-3.46) 1.45 (0.89-3) 1.9 (1.11-3.7) 0.001 
SBP (mmHg) 121.44±18.06 121.69±16.23 121.21±19.66 0.246 
DBP (mmHg) 79.12±11 79.85±10.44 78.42±11.48 0.025 
Diabetics (%) 7.45% (69.926) 7.51% (34.453) 7.4% (35.473) 0.771 
Smoker (%) 24.44% (228.933) 29.61% (135.456) 19.5%(93.477) 0.001  
Hypertensive (%) 22.07% (203.920) 22.27% (100.449) 21.87% (103.471) 0.883 
Hyperlipidemic (%) 36.02% (335.930) 32.68% (149.456) 39.24% (186.474) 0.037  
Anti-HSP 27 (OD) 0.23(0.1-0.43) 0.24 (0.11-0.43) 0.22 (0.1-0.43) 0.563 
BMI, body mass index; FBG, fasting blood sugar; WC, waist circumferences; HC, hip circumferences; WHR, 
waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; hs-CRP, high-sensitivity C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure.  
Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as SBP of ≥140 mmHg 
and DBP of ≥90 mmHg. Hyperlipidemia was defined as a total cholesterol ≥5.2 mmol/L (200 mg/dL), 
triglycerides ≥1.5 mmol/L (150 mg/dL), and HDL-C <0.9 mmol/L (40 mg/dL) (for men) and <1.29 mmol/L (50 
mg/dL) (for women). 
Values are expressed as mean±SD, and interquartile range or median and Mann–Whitney U test were used for 
normally and non-normally distributed data, respectively. 
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Table 2: Comparison of clinical and biochemical characteristics between subgroups for age 
Age (year) 35-44 45-54 55-65 p-value 
number 393 349 191 - 
Height (m) 1.63±0.09 1.62±0.09 1.6±0.1 0.004 
Weight (kg) 74.08±14.45 72.82±12.11 73.26±12.1 0.783 
BMI (kg/m
2
) 27.81±5.05 27.72±4.57 28.53±4.42 0.047 
FBG (mg/dl) 85.73±27.18 91.85±35.74 96.17±46.61 0.001 
WC (cm) 94.28±12.36 95.65±12.11 98.11±11.93 0.001 
HC (cm) 104.2±9.74 103.34±9.12 103.47±8.95 0.53 
WHR 0.91±0.11 0.93±0.08 0.95±0.07 0.001 
Serum LDL-C (mg/dL) 109.81±36.14 118.83±35.94 124.46±37.15 0.001 
Serum HDL-C (mg/dL) 41.84±9.68 43.4±10.54 41.85±9.08 0.118 
Serum TG (mg/dL) 112 (77.25-157.75) 119 (84-166) 124 (99.75-186.25) 0.002 
Serum hs-CRP (mg/dL) 1.54 (0.9-3.02) 1.62 (1.08-3.3) 2.01 (1.08-5.08) 0.006 
SBP (mmHg) 115.11±14.53 123.23±17.21 131.19±20.91 0.001 
DBP (mmHg) 76.52±10.76 80.25±10.67 82.39±10.93 0.001 
Diabetics (%) 5.13% (20/390) 8.96% (31/346) 9.47% (18/190) 0.003 
Smoker (%) 27.99% (110/393) 22.06% (77/349) 21.47% (41/191) 0.097 
Hypertensive (%) 14.21% (55/387) 23.77% (82/345) 35.11% (66/188) 0.001 
Hyperlipidemic (%) 28.75% (113/393) 38.9% (135/347) 45.79% (87/190) 0.001 
Anti-HSP 27 (OD) 0.29±0.26 0.32±0.28 0.33±0.29 0.134 
BMI, body mass index; FBG, fasting blood sugar; WC, waist circumferences; HC, hip circumferences; WHR, 
waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; hs-CRP, high sensitivity c-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure.  
Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as a SBP ≥140 mmHg 
and a DBP ≥90 mmHg. Hyperlipidemia was defined as a total cholesterol (TC) ≥5.2 mmol/l (200 mg/dl), 
triglycerides (TG) ≥1.5 mmol/l (150 mg/dl), and HDL-C <0.9 mmol/l (40 mg/dl) (for men), and <1.29 mmol/l 
(50 mg/dl)(for women). 
Values are expressed as mean±SD or median(interquartile range) and One-Way ANOVA and Kruskal Wallis 
test were used for normal and non-normal distributed data, respectively. 
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Table 3: Comparison of clinical and biochemical characteristics between subgroups of BMI 
p-value normal weight overweight obese  
- 256 393 283 number 
0.104 46.95±8.15 47.16±7.78 48±8.07 Age (year) 
0.001 1.65±0.09 1.63±0.09 1.59±0.09 Height (m) 
0.001 61.23±8.21 72.94±8.2 85.19±11.92 Weight (kg) 
0.001 22.4±1.97 27.52±1.39 33.49±3.06 BMI (kg/m
2
) 
0.006 87.72±40.5 89.46±30.3 93.14±36.48 FBG (mg/dl) 
0.001 84.98±8.32 94.66±8.54 106.4±10.53 WC (cm) 
0.001 95.41±5.01 102.51±5.9 112.9±8.15 HC (cm) 
0.001 0.89±0.07 0.93±0.11 0.94±0.07 WHR 
0.013 112.73±33. 115.21±38. 120.58±36.79 Serum LDL-C (mg/dL) 
0.047 43.67±10.1 42.09±10.3 41.8±8.96 Serum HDL-C (mg/dL) 
0.001 92.5 (66.75-125) 124 (89.25-178) 130(104.25-179.75) Serum TG (mg/dL) 
0.001 1.22 (0.75-2.3) 1.51 (0.97-2.79) 2.81 (1.47-5.63) Serum hs-CRP (mg/dL) 
0.001 117.02±16.0 121.37±17.0 125.52±19.64 SBP (mmHg) 
0.001 76.19±10.7 79.18±10.5 81.68±11.15 DBP (mmHg) 
0.033 5.1%  7.7%  8.9% (25/281) Diabetics (%) 
0.714  25.39%  24.17%  24.03% (68.283) Smokers (%) 
0.003  17.06%  21.13% (82/388) 27.86% (78/280) Hypertensive (%) 
0.001  25.88%  39.03%  41.13%  Hyperlipidemic (%) 
0.046  0.23 (0.1-0.42) 0.21 (0.1-0.42) 0.27 (0.12-0.48) Anti-HSP27 (OD) 
BMI, body mass index; FBG, fasting blood sugar; WC, waist circumferences; HC, hip circumferences; WHR, 
waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; hs-CRP, high sensitivity c-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as a SBP ≥140 mmHg 
and a DBP ≥90 mmHg. Hyperlipidaemia was defined as a total cholesterol (TC) ≥5.2 mmol/l (200 mg/dl), 
triglycerides (TG) ≥1.5 mmol/l (150 mg/dl), and HDL-C <0.9 mmol/l (40 mg/dl) (for men), and <1.29 mmol/l 
(50 mg/dl)(for women). 
Values are expressed as mean±SD, and interquartile range or median and Mann–Whitney test were used for 
normality and non-normality distributed data, respectively. 
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Table 4: Comparison of clinical and biochemical characteristics between subgroups of educational attainment 
p-
value 
PhD or MD 
Bachelor or 
Postgraduate 
Diploma High School 
Secondary 
School 
Primary 
School 
 
- 6 69 27 362 358 110 Number 
0.001 47.5±4.32 46.73±7.57 47.74±8.15 45.15±7.08 47.98±8 53.07±8.08 Age (year) 
0.001 1.68±0.08 1.68±0.08 1.68±0.07 1.64±0.1 1.61±0.08 1.57±0.09 Height (m) 
0.041 84.67±14.69 73.47±14.37 75.41±11.28 75±13.98 72.63±12.28 70.34±11.7 Weight (kg) 
0.001 30.26±6.37 25.99±4.06 26.84±4.34 27.88±4.9 28.2±4.61 28.7±4.79 BMI (kg/m
2
) 
0.153 113±50.63 88.55±38.16 90.38±29.19 88.37±32.29 90.5±30.22 95.36±54.78 FBG (mg/dL) 
0.001 101±11.1 90.51±11.07 92.9±10.77 93.99±11.71 97.14±12.64 99.3±12.21 WC (cm) 
0.045 107.08±11.67 100.4±7.19 102.09±6.97 103.62±9.9 104.46±9.24 104.06±9.11 HC (cm) 
0.001 0.94±0.03 0.9±0.07 0.91±0.07 0.91±0.12 0.93±0.08 0.95±0.07 WHR 
0.063 100.16±20.17 114.46±39.52 118.96±38.76 111.92±33.7 118.99±37.67 123.23±39.14 Serum LDL-C (mg/dL) 
0.042 37.43±6.67 42.22±9.61 41.03±8.53 41.55±9.92 42.98±10.06 44.42±9.91 Serum HDL-C (mg/dL) 
0.286 
192.5 (114-
267.25) 
114.5 (74.75-
170.75) 
112 (63-176) 
113 (83.75-
162) 
118 (83-161) 
128 (96.75-
178) 
Serum TG (mg/dL) 
0.006 
3.92 (1.42-
9.05) 
1.18 (0.68-
2.32) 
1.37 (0.77-
5.75) 
1.51 (0.9-
3.21) 
1.64 (1.06-
3.63) 
1.9 (1.27-
4.29) 
Serum hs-CRP (mg/dL) 
0.001 133.39±14.85 119.79±16.32 115.75±16.96 118.51±16.16 122.63±18.2 129.56±21.65 SBP (mmHg) 
0.013 86.84±10.99 78.39±11.18 77.48±10.55 78.17±10.15 79.47±11.42 81.97±11.7 DBP (mmHg) 
0.516 33.33% (2/6) 7.58% (5/66) 7.69% (2/26) 
6.44% 
(23/357) 
8.15% 
(29/356) 
7.41% 
(8/108) 
Diabetics (%) 
0.245 33.33% (2/6) 
18.18% 
(12/66) 
22.22% 
(6/27) 
20.89% 
(75/359) 
27.65% 
(99/358) 
30% (33/110) Smoker (%) 
0.001 50% (3/6) 
19.05% 
(12/63) 
25.93% 
(7/27) 
15.86% 
(56/353) 
24.23% 
(86/355) 
34.86% 
(38/109) 
Hypertensive (%) 
0.14 66.67% (4/6) 
34.85% 
(23/66) 
37.04% 
(10/27) 
30.64% 
(110/359) 
38.94% 
(139/357) 
43.52% 
(47/108) 
Hyperlipidemic (%) 
0.295 
0.23 (0.08-
0.59) 
0.22 (0.08-
0.41) 
0.2 (0.07-
0.45) 
0.26 (0.13-
0.44) 
0.21 (0.1-
0.43) 
0.21 (0.09-
0.43) 
Anti-HSP 27 (OD) 
BMI, body mass index; FBG, fasting blood sugar; WC, waist circumferences; HC, hip circumferences; WHR, 
waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; hs-CRP, high sensitivity c-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as a SBP ≥140 mmHg 
and a DBP ≥90 mmHg. Hyperlipidaemia was defined as a total cholesterol (TC) ≥5.2 mmol/l (200 mg/dl), 
triglycerides (TG) ≥1.5 mmol/l (150 mg/dl), and HDL-C <0.9 mmol/l (40 mg/dl) (for men), and <1.29 mmol/l 
(50 mg/dl)(for women). 
Values are expressed as mean±SD, and interquartile range or median. Kruskal–Wallis and Chi-square tests were 
used. 
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Table 5: Comparison of clinical and biochemical characteristics between subgroups of employment status 
p-value Retired Unemployed Employed  
- 84 435 414 Number 
0.001 54.65±6.46 47.53±8.02 45.69±7.32 Age (year) 
0.001 1.66±0.09 1.56±0.07 1.68±0.08 Height (m) 
0.001 74.57±12.32 70.57±11.68 76.24±14.12 Weight (kg) 
0.001 27.06±3.96 28.9±4.67 27.07±4.8 BMI (kg/m
2
) 
0.411 92.07±32.89 91.2±40.93 88.68±28.89 FBG (mg/dl) 
0.012 94.09±11.13 96.85±12.86 94.53±11.69 WC (cm) 
0.001 101.29±7.95 105.25±9.49 102.58±9.2 HC (cm) 
0.39 0.93±0.07 0.92±0.9 0.92±0.11 WHR 
0.507 114.55±38.39 117.43±35.5 115.18±37.61 Serum LDL-C (mg/dL) 
0.001 41.85±10.31 43.98±9.46 40.91±10.06 Serum HDL-C (mg/dL) 
0.273 122.5 (94-182) 113 (82-161.25) 120 (84-170) Serum TG (mg/dL) 
0.02 1.59 (1.03-3.02) 1.84 (1.12-3.59) 1.44 (0.89-3.3) Serum hs-CRP (mg/dL) 
0.011 126.49±16.62 121.41±20.11 120.44±15.76 SBP (mmHg) 
0.026 82.33±9.71 78.61±11.69 79.01±10.4 DBP (mmHg) 
0.96 8.33% (7/84) 7.89% (34/431) 6.81% (28/411) Diabetics (%) 
0.014 16.67% (14/84) 21.84% (95/435) 28.74% (119/414) Smokers (%) 
0.369 27.71% (23/83) 22.27% (96/431) 20.69% (84/406) Hypertensive (%) 
0.436 34.52% (29/84) 38.19% (165/432) 34.06% (141/414) Hyperlipidemic (%) 
0.183 0.28 (0.15-0.47) 0.23 (0.1-0.44) 0.23 (0.1-0.41) Anti-HSP27 (OD) 
BMI, body mass index; FBG, fasting blood sugar; WC, waist circumferences; HC, hip circumferences; WHR, 
waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; hs-CRP, high sensitivity c-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as a SBP ≥140 mmHg 
and a DBP ≥90 mmHg. Hyperlipidemia was defined as a total cholesterol (TC) ≥5.2 mmol/l (200 mg/dl), 
triglycerides (TG) ≥1.5 mmol/l (150 mg/dl), and HDL-C <0.9 mmol/l (40 mg/dl) (for men), and <1.29 mmol/l 
(50 mg/dl)(for women). 
Values are expressed as mean±SD, and interquartile range or median. Kruskal–Wallis and Chi-square tests were 
used. 
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Table 6: Association between anti-HSP27 antibody levels and risk factors of 
atherosclerosis using general linear model analysis 
Parameter Estimates 
Dependent Variable: Anti_HSP27 
Parameter β Std. 
Error 
t p-value 
Intercept -1.901 0.974 1.951 0.051 
Age 0.001 0.001 0.789 0.430 
Height 1.216 0.587 2.072 0.039 
Weight -0.012 0.006 1.948 0.052 
BMI 0.037 0.017 2.210 0.027 
WHR 0.100 0.103 0.972 0.331 
Serum LDL-C -0.002 0.001 3.988 0.000 
Serum HDL-C -0.002 0.001 1.648 0.100 
Serum TG 0.000 0.000 3.620 0.000 
Serum total cholesterol 0.002 0.001 2.842 0.005 
Serum hs-CRP 0.001 0.001 0.687 0.492 
Diabetes  -0.040 0.036 1.123 0.262 
Smokers -0.020 0.032 0.623 0.534 
Hypertension 0.006 0.023 0.271 0.786 
Hyperlipidemia 0.032 0.031 1.040 0.299 
BMI, body mass index; WHR, waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-
density lipoprotein cholesterol; TG, triglycerides; hs-CRP, high sensitivity c-reactive protein. 
Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as a SBP ≥140 mmHg 
and a DBP ≥90 mmHg. Hyperlipidemia was defined as a total cholesterol (TC) ≥5.2 mmol/l (200 mg/dl), 
triglycerides (TG) ≥1.5 mmol/l (150 mg/dl), and HDL-C <0.9 mmol/l (40 mg/dl) (for men), and <1.29 mmol/l 
(50 mg/dl)(for women). 
General linear model analysis was performed as dependent variable (anti-HSP27) is quantitative and 
independent variables are both qualitative and quantitative. 
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1. Serum anti-HSP27 antibody titers have an important role as biomarker in obese 
subjects  
2. Obese subjects had a significantly higher anti-HSP27 antibody levels than the 
nonobese group 
3. Serum anti-HSP27 antibody titers did not differ with gender 
4. Serum anti-HSP27 antibody titers are related to several cardiovascular risk factors 
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